The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through the Kansas City Clinical Oncology Program (KCCOP), Sarah Cannon Research Institute, and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

AML 48: A Phase II Study of CPX-351 (Vyxeos™) w/Quizartinib for R/R FLT3-ITD Mutation-Positive AML. PI: Suman Kambhampati, MD
Facility: Research Medical Center

BMT 24: Phase 2 Study of Nivolumab as consolidation after autoSCT in Hodgkins lymphoma at risk of relapse or progression. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CLL 39: Study of Ublituximab + TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CLL 48: Phase 3 Study of Zanubrutinib vs Ibrutinib in R/R Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CLL 49: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 120: Phase 2b Study of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Previously Treated DLBCL. PI: Suman Kambhampati, MD
Facility: Research Medical Center, Menorah Medical Center

LYM 155: Phase 2 Study of Acalabrutinib as Post-AutoSCT Maintenance Therapy in Subjects with MCL. PI: Suman Kambhampati, MD.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 162: A Phase 2, Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Indolent Non-Hodgkin Lymphoma (iNHL). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM 109: Study of Dara + Len vs. Lenalidomide Alone as Maint. in newly diagnosed Multiple Myeloma Who Are MRD + after Frontline AutoSCT. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 304: A phase III, randomized, placebo-controlled, multicenter study of the efficacy and safety of atezolizumab plus chemotherapy in the treatment of early-relapsing locally recurrent inoperable or metastatic triple-negative breast cancer. PI: Dr Stephanie Graff
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 310:

Phase III, Study of Atezolizumab + Standard Adjuvant Anthracycline/Taxane-Based Chemo Versus Chemo Alone In Operable TNBC. PI: Stephanie Graff, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 312:

Phase III trial of xentuzumab in combo w/everolimus and exemestane vs everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease. PI: Stephanie Graff, MD


Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 318: Phase 3, Study Of DS-8201A vs Treatment Of Choice For Her2 +, Unresectable &/Or MBC Pretreated w/ Prior SOC HER2 Therapies, Including T-DM1. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 328: Open, Randomized, Study of Lasofoxifene Relative to Fulvestrant in Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 336: A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 342: Phase 3 Study Of GDC-0077 + Palbociclib And Fulvestrant vs Placebo + Palbociclib And Fulvestrant In Locally Adv/met PIK3CA-Mutant HR +, HER2- BC. PI: Stephanie Graff, MD<
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 343: Phase 3 study of tucatinib or placebo + T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 346: Phase 3 Trial Comparing Eribulin w/wo Balixafortide in Patients with Locally Recurrent and Metastatic Breast Cancer. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

BRE 348: Phase III Study of Capivasertib + Fulvestrant Vs Placebo + Fulvestrant for Locally Adv/Met HR +/HER2? Breast Cancer after Recurrence or PD On/After AI. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Amaze – SentreHeart: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

Amulet – Abbott: Study to determine if Amulet device is safe and effective when compared to Watchman device. Randomized 1:1 Watchman vs Amulet. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

ASAP Too – Boston Scientific: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Yoaav Krauthammer
Facility: Overland Park Regional Medical Center, Research Medical Center

Catalyst – Abbott: The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

Diamond AF II – Epix: Evaluate the safety and effectiveness of the Diamond tipped catheter ablation system. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Node 301 – Milestone: Determine whether etripamil nasal spray 70 mg self-administered by patients is superior to placebo at terminating episodes of PSVT in an outpatient setting. This is a study that involves the patient coming back for a 2 hour Research visit at OPR. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Xe-POHCAS – Neuroprote Xeon Inc.: Evaluation on Days 30 and 90 post OHCA, whether there is a difference in functional outcome in comatose subjects who achieved ROSC within 30 minutes after OHCA and were treated with xenon 50% plus oxygen vs standard of care treatment without xenon during TTM. PI:Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

GI 268: Study of TTFields, 150kH + gemcitabine and nab-paclitaxel for FL locally-advanced pancreatic adenocarcinoma. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GI 298: Phase 3 study of irinotecan liposome injection, oxaliplatin, 5-FU/leucovorin vs nab-paclitaxel + gem. as front line for met. pancreatic adenocarcinoma. PI: Mohammad Mozayen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GU 175: Phase 3 Study of Cabozantinib in Combo w/Nivolumab and Ipilimumab vs Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic RCC of Intermediate or Poor Risk. PI: Mohammad Mozayen, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

GYN 87: Phase 3 trial of maintenance with selinexor/ placebo after combination chemo for advanced or recurrent endometrial cancer. PI: Kristopher LyBarger, DO
Facility: Centerpoint Medical Center, Research Medical Center

GYN 95: SORAYA: Phase 3, Study of Mirvetuximab Soravtansine in Adv High-Grade Epi. Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression. PI: PI: Kristopher LyBarger, DO
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

CNS 25: Phase 3 Study of Lomustine w/wo Eflornithine in Anaplastic Astrocytoma That Progress/Recur After RT and Adj. Temozolomide. PI: Amandeep Kalra. MD
Facility: Menorah Medical Center, Research Medical Center

LUN 402: Phase 3 Study of Sitravatinib + Nivolumab VS Docetaxel in Advanced Non-Squamous NSCLC with PD After Platinum Chemo + CPI. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 404: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAFV600E-mutant Non-small Cell Lung Cancer. PI: Syed Karim, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 413: A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 419: Phase 3 Study of AMG 510 vs Docetaxel in previously treated Locally Adv/Met NSCLC with Mutated KRASp.G12C. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 426: Phase I/III Study of Atezolizumab & Tiragolumab vs Durvalumab in Unresectable Stage 3 NSCLC who are stable after platinum chemoradiation. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 429: Phase 2 Study of Telaglenastat or Placebo w/Pembor & Chemo in FL Met. KEAP1/NRF2-mutated Non-Sqa NSCLC. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LUN 430: Phase 2 Study of AB122 alone, AB154 + AB122, and AB154 + AB122 and AB928 in Front-Line, NSCLC. Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MULTI 29: A Phase II study of atezolizumab in patients with NSCLC and advanced solid tumors that have had prior treatment with a PD-1 inhibitor. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

PRO 10: A Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations. PI: Stephanie Graff, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center